Trial · NCT07903337
Registered outcomes34
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 34
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Stage 1 Area under the curve [AUC] from time 0 to the last quantifiable time [AUC0-t] | Day 1 to Day 4 of each single dose period | |
| Primary | Stage 1 AUC from time 0 to infinity [AUC0-∞], and maximum concentration [Cmax] | Day 1 to Day 4 of each single dose period | |
| Primary | Stage 1 Time to Cmax (Tmax) | Day 1 to Day 4 of each single dose period | |
| Primary | Stage 1 Half-life (t1/2) | Day 1 to Day 4 of each single dose period | |
| Primary | Stage 1 Apparent clearance (CL/F) | Day 1 to Day 4 of each single dose period | |
| Primary | Stage 1 Apparent volume of distribution (Vz/F) | Day 1 to Day 4 of each single dose period | |
| Primary | Stage 2 Incidence and severity of TEAEs and TESAEs, | From Day 1 to Day 21 (EOS visit) | |
| Primary | Stage 2 Physical examination | Screening, Day -1, Day 21 | |
| Primary | Stage 2 Vital signs | Screening, Day -1 to Day 21 | |
| Primary | Stage 2 Laboratory tests | Screening, Day -1, Day 7, Day 14, Day 21 | Hematology, biochemistry, urinalysis, and coagulation |
| Primary | Stage 2 12-lead ECG | Screening, Day 1, Day 14, Day 21 | |
| Secondary | Stage 1 Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) | From Day 1 to EOS visit | |
| Secondary | Stage 1 Physical examination | Screening, Day -1, Day 4, Day 7 of each single dose period | |
| Secondary | Stage 1 Vital signs | Screening, Day -1, Day 1, Day 2, Day 3, Day 4, Day 7 of each single dose period | |
| Secondary | Stage 1 Laboratory tests | Screening, Day -1, Day 4, Day 7 of each single dose period | Hematology, biochemistry, urinalysis, and coagulation |
| Secondary | Stage 1 12-lead electrocardiogram (ECG) | Screening, Day 1, Day 4, Day 7 of each single dose period | |
| Secondary | Stage 2 AUC during a dosing interval (AUCτ) | From pre-dose on Day 1 to 12 hours after the morning administration on Day 14 | |
| Secondary | Stage 2 AUC from 0 to 24 hours (AUC0-24) | From pre-dose on Day 1 to 12 hours after the morning administration on Day 14 | |
| Secondary | Stage 2 Cmax | From pre-dose on Day 1 to 12 hours after the morning administration on Day 14 | |
| Secondary | Stage 2 Tmax | From pre-dose on Day 1 to 12 hours after the morning administration on Day 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07903337/registered